Buyback of INR 81 crore plus new Director (Finance) appointed

Management Changes View source PDF Explain this filing

NECLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+16.4%Reaction day

₹18.00

prior close

₹20.60

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%+16.9% vs market

On the reaction day the stock moved 16.9 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.9

10m

-2.9

15m

-3.1

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

+16.4-0.5+16.9

Next day

+16.5-1.7+18.2

+13.8-4.0+17.8

+16.4-2.1+18.5

+16.8-2.7+19.5

+16.6-2.3+18.9

+16.9-1.5+18.4

15d

+11.6-1.8+13.4

+6.2+0.1+6.1

-23.7-3.3-20.3

-35.1-11.2-23.9

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Nectar Lifesciences board approved a share buyback of up to 3 crore equity shares at INR 27 each, totaling INR 81 crore, via tender offer route. Promoters won't participate. Record date is Dec 24, 2025. Board also appointed Mr. Sushil Kapoor (Chartered Accountant, Company Secretary, age 67, 38 years finance experience) as Director (Finance) for 3 years from Dec 4, 2025. Shareholder approval for his appointment will be sought through postal ballot.

Likely market impact

Buyback signals board confidence in valuation; promoter holding rises from 44.91% to 51.84% post-buyback. New finance director brings experienced leadership.